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While vaccine development is a major theme of IHV meetings,
other prevention research approaches are not necessarily on
the radar scope of the basic science and clinical researchers
seeking state-of-the-art updates. The HIV Prevention Trials
Network and the Microbicide Trials Network are engaged a
wide variety of prevention clinical trials. Other trials are
underway with other sources of support. This presentation
will highlight current challenges in:
-Barrier research, including microbicides and diaphragms
-Male circumcision and its rationale
-Use of antiretroviral therapy and transmission prevention
-Use of opportunistic infection and helminth treatment to
reduce viral load and infectiousness
-Control of sexually transmitted diseases to reduce HIV
transmission efficiency
-Selected highlights in treatment of drug abuse to reduce HIV
risk, prevention of mother-to-child HIV transmission, and in
behavior change research for prevention.
The goal for this presentation is to challenge the basic science
and clinical research communities to identify important partner-
ships that can enhance the scientific value of key prevention
clinical trials, as well as to address underlying mechanisms of
approaches that show promise as new tools.
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West Nile Virus (WNV) is a re-emerging pathogen and a well-
known agent of fatal encephalitis in several species, including
mouse and man; however immunopathogenic mechanisms are
poorly understood. We found that WNV induced upregulation
of the chemokine receptor/HIV coreceptor CCR5 and its ligand
CCL5 in mouse brain, as well as influx of effector leukocytes,
including CD4+ and CD8+ T cells, NK cells, and macrophages,
of which ~25% expressed CCR5. Infection of CCR5-/- mice was
rapidly and uniformly fatal, whereas the majority of CCR5+/+
mice survived. Consistent with this, CCR5 32 homozygotes
were overrepresented in three of three cohorts of symptomatic
WNV seropositive individuals compared to control populations.
And were more likely to have a fatal outcome. CCR5 appears to
mediate resistance to fatal WNV infection in mouse and man by
coordinating leukocyte recruitment to the infected brain. Thus
CCR5 32 homozygosity is a strong genetic risk factor for
symptomatic WNV infection in man. The results suggest that
therapeutic blockade of CCR5 may carry increased risk of
symptomatic and possibly fatal outcome should individuals
become infected with WNV.
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HIV-1C of southern Africa shows higher rates of genomic
variation than does HIV-1B. Prevalence rates are far higher in
this region as compared to elsewhere in sub-Saharan Africa or in
the world. Enhanced rates of transcriptional activation, pre-
sumably related to duplication in the LTR NF-kB enhancer
region of the genome, have been well documented. This may in
turn be associated with better replication in vaginal and GALT
tissues, different patterns of mother/infant transmission, and
elevated transmission rates. HIV-1C has also been shown to
have higher rates of nevirapine resistance in mothers given labor
nevirapine, higher rates of K65R resistance to tenofovir after in
vitro selection, different patterns of accumulation of thymide
analogue mutations to the nucleoside analogue drugs, and
different patterns of mutations to the protease inhibitor drugs.
HIV-1C also shows different patterns of immunoselection for
immunodominant epitopes to both CTL and antibody
responses. With the gag gene epitopes, for example, the p17
region is immunodominant in HIV-1B while the p24 region is
immunodominant for HIV-1C. How these responses may be
related to differences in major histocompatibility alleles in the
people of southern Africa is unclear.
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The humoral arm of the immune system exerts continual
selective pressure on HIV replication in the infected person. We
have described a conserved epitope within the gp120 V3 loop
that is masked in the native Env trimer on CCR5-restricted (R5)
HIV-1 virions, but fully exposed on CXCR4-using (X4, R5X4)
virions. The ability of a monoclonal antibody against this epitope
to selectively neutralize CXCR4-using but not CCR5-restricted
primary isolates raises the question of whether in vivo
neutralizing antibody selection pressure in the acutely infected
person plays a major role in the selective transmission of R5
viruses.
We are exploiting antibodies to engineer novel bifunctional
proteins against HIV infection. One agent, designated sCD4-17b,
is based on the sequential receptor binding mechanism of gp120:
first to CD4, then to coreceptor. The sCD4 moiety of the
chimeric protein binds and induces the conformational change
required to expose/create the highly conserved ‘‘bridging sheet’’
involved in coreceptor binding and containing the 17b epitope.
The potent neutralizing activity of sCD4-17b against diverse
HIV-1 primary isolates suggests its potential utility as a topical
microbicide to protect against HIV-1 sexual transmission [1,2].
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We have described a constitutive activation of naturally C-
terminus truncated STAT5 (STAT5!) in PBMC of most HIV+
individuals (C. Bovolenta, Blood, 1999). We here report that the
chronically HIV-infected promonocytic cell line U1 expresses
exclusively a STAT5! isoform similar to that of PBMC of HIV+
individuals in virtual absence of STAT5FL. Consistently with the
presence of functional STAT5 DNA binding sites in the HIV-1
LTR (Selliah et al., Virology, 2006), GM-CSF stimulation of U1
cells led to a modest induction of HIV expression as well as to
the activation of both STAT5! and of an ERK-1/2-AP-1
pathway. Inhibition of ERKs/AP-1 by PD98059 abolished GM-
CSF induced HIV expression in U1 cells, whereas inhibition of
STAT5! expression by either AG490 or anti-STAT5 siRNA
resulted in a significant enhancement of GM-CSF induced HIV
expression in U1 cells. Finally, ex vivo IL-2 stimulation of PBMC
from most HIV+ individuals in the presence of anti-STAT5
siRNA resulted in the enhancement of HIV-1 p24 Gag antigen
expression. Thus, STAT5! is likely a novel natural inhibitor of
HIV expression both in vitro and in vivo.
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We describe how CIITA exerts a dual role against retroviral
infection. The first, classical role is the upregulation of MHC
class II expression and thus the capacity to present viral antigens
to CD4+ T cells. The other, evolutionary new and fundamental
role is to inhibit viral replication by blocking specifically the
function of the viral transactivators. HIV-1 Tat is inhibited
through the competition for cyclin T1 of the P-TEFb complex,
whereas HTLV-2 Tax-2 is inhibited through a concerted action
which may increase the binding affinity of the CIITA-NFY
complex for Tax-2, displacing it from the viral LTR promoter. As
expected, two distint sequences in the N-term region of CIITA
mediate the inhibitory action on Tat and Tax-2, respectively. Of
note, Tax-1 from HTLV-1 seems also to be inhibited by the same
sequence that inhibits HTLV-2 Tax-2. Interestingly, only those
CIITA fragments containing the minimal inhibitory domains that
localize into the nucleus could exert an effective suppressive
action. Taken together, our results indicate that CIITA is an
extant molecular tool endowed with distinct evolving functions
against retroviruses. These distinct properties of CIITA will
shed new light on the molecular mechanisms of adaptive
coevolution of hosts and pathogens and may be exploited to
envisage novel therapeutic strategies aimed at counteracting
retroviral infections.
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SOCS-1 expression from dendritic cells
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Suppressor of cytokine signaling-1 (SOCS-1) is an inducible
negative regulator of the JAK/STAT signal pathway; SOCS-1 is
expressed in dendritic cells (DCs) and negatively regulates
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